繁體
  • 简体中文
  • 繁體中文
×

熱門資訊> 正文

InMed Pharma收到纳斯达克不合规通知

2026-03-28 05:12

  • InMed Pharmaceuticals (INM) received a notice from Nasdaq for failing the $1 minimum bid price requirement.
  • The deficiency follows shares trading below $1.00 for 30 consecutive trading days (Feb 11–Mar 26, 2026).
  • The notice has no immediate impact, and shares will continue trading.
  • InMed has a 180-day period to regain compliance by achieving a $1.00+ closing price for 10 consecutive days.
  • The company may qualify for an additional 180-day extension if other listing criteria are met.
  • InMed may consider actions such as a reverse stock split to regain compliance.
  • Failure to meet requirements could lead to delisting, though the company has the right to appeal.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
（工作日09：30 - 次日05：30）
客戶端：
關注我們：
  • 微信公眾號二維碼

© 2026 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號